AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00718328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
Study NCT00199290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombination)
Study NCT00709813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))
Description: Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
Study NCT02908789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Description: Selective caries removal + Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms + tooth restauration
Study NCT02908789 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Without Antimicrobial phothodynamic therapy
Description: Selective caries removal + tooth restauration
Study NCT00742729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: Educational small group session with free FOBT kit
Study NCT00742729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 2
Description: Educational small group session with no FOBT kit
Study NCT03853525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semisolid vaseline
Description: Product is applied to one side of the inguinal region.
Study NCT02973035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Study NCT02973035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Study NCT00742729 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Arm 3
Description: Educational small group session, exercise
Study NCT02479815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Micronutrient Powder (MNP)
Description: Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
Study NCT02286635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort and rifampin
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
Study NCT02286635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort and Clarithromycin
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
Study NCT01474720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax vaccine
Description: Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
Study NCT01474720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zostavax vaccine
Description: Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
Study NCT04623229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCS
Description: Manual Cataract Surgery
Study NCT04623229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReLACS Early
Description: ReLACS with early administration of anesthesia
Study NCT04623229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReLACS Standard
Description: ReLACS with standard time administration of anesthesia
Study NCT03224442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: soft tissue augmentation by prf
Study NCT03224442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal Pedicle
Description: soft tissue augmentation by palatal pedicle
Study NCT05089773 — intervention group
Intervention type: PROCEDURE
Intervention: The arterial switch operation
Description: The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta.
Study NCT03005691 — intervention group
Intervention type: RADIATION
Intervention: Spectroscopy
Description: Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.
Study NCT03005691 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
Study NCT02554578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary follow-up programme supported by mHealth
Description: The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families.
Study NCT03972878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control snack
Description: dry fruit snack (200 kcal) + 250 ml water
Study NCT03972878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control cream
Description: commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
Study NCT03972878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream version 1
Description: commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
Study NCT03005691 — intervention group
Intervention type: PROCEDURE
Intervention: Conditioned Pain Modulation
Description: Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
Study NCT04981080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.
Study NCT03972878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream version 2
Description: commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
Study NCT03972878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream version 3
Description: commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
Study NCT03972878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control chocolate bar
Description: commercial chocolate bar (200 kcal)+ 250 ml water
Study NCT00699582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
Study NCT00699582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
Study NCT03972878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chocolate bar version 1
Description: commercial chocolate bar (200 kcal), version 1+ 250 ml water
Study NCT00699582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
Study NCT00561964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
Study NCT02429791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
Study NCT02429791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
Study NCT02429791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAR
Description: CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
Study NCT00199290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trafermin (genetical recombination)
Study NCT05210686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subgingival re-instrumentation
Description: subgingival re-instrumentation (control)
Study NCT05210686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subgingival re-instrumentation
Description: subgingival re-instrumentation (control)
Study NCT01385475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT
Description: 8 week RT Intervention
Study NCT01577667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellivent; automatic mode implemented on a S1 ventilator
Description: Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
Study NCT00903617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: 5 mg for 8 weeks
Study NCT00903617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: 50 mg for 8 weeks
Study NCT00903617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: 150 mg for 8 weeks
Study NCT00903617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for 8 weeks
Study NCT00903617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niaspan
Description: 1500 mg for 8 weeks
Study NCT00561964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo group: 2 placebo capsules daily as a single morning intake
Study NCT03185637 — intervention group
Intervention type: PROCEDURE
Intervention: Various interventions for each of the conditions.
Description: This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair.
Study NCT00903617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: x mg for 8 weeks based from data from Part A
Study NCT00903617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073
Description: optional dose based on data from Part A
Study NCT04425746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Study NCT02893618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline controlled-release tablet
Description: QD tablet formulation of choline salt of diazoxide
Study NCT04425746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00089570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terlipressin
Study NCT00089570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01940926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
Study NCT00635804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3281
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
Study NCT00885599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal API
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study NCT00504751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna, cisplatin, etoposide, rituximab
Description: VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5
Study NCT02291575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: (please see Arm Description)
Study NCT02291575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
Study NCT03506256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 MG
Description: Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
Study NCT02856802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 10 mg Nasal Spray
Description: 100 μL nasal spray once
Study NCT02856802 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sumatriptan Placebo Nasal Spray
Description: 100 μL nasal spray once
Study NCT03768362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plication strabismus surgery
Description: The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.
Study NCT03768362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection strabismus surgery
Description: resection strabismus surgery
Study NCT00051935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa
Description: 20 mg/kg (qow); intravenous
Study NCT00635804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-3281
Description: Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
Study NCT04046029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
Study NCT04046029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
Study NCT00660829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00660829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% Azelastine Hydrochloride
Description: 0.15% Azelastine Hydrochloride 822 mcg
Study NCT02218424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Study NCT02218424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT03395613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWT
Description: Negative pressure wound thearpy on closed surgical wounds
Study NCT01783795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Genetic Analysis
Study NCT00885599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cepacol
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study NCT00885599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listerine Antiseptic Mouth Rinse
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study NCT00885599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo mouthwash
Description: colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Study NCT03759340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI 502 0.46% Topical Solution
Description: apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)